ClinicalTrials.gg
BiologicalDrug

Efgartigimod alfa clinical trials

Also written Efgartigimod, ARGX-113 and Vyvgart.

studies test it
66
open now
26
in phase 3
30
first study started
2015

How each study uses efgartigimod alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the efgartigimod alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Dec 2021 · VYVGART · BLA 761195 (FDA, Drugs@FDA)
European Union
10 Aug 2022 · Vyvgart · EMEA/H/C/005849 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Efgartigimod IV
11
Efgartigimod Alfa
4
Efgartigimod Alfa-Fcab
2

Brand

Vyvgart
5

Development codes

ARGX-113
10

Other names

Efgartigimod
18

In one entry with another drug

Given together, or one or the other

Efgartigimod PH20 SC
22
ARGX-113 PH20 SC
2

Studies by the year they started

65 studies that test it; most in 2025 (14); 1 more planned to start later

Studies that test efgartigimod alfa, by start year
YearStudies
20151
20161
20173
20181
20193
20206
20217
20222
20239
202412
202514
20266

Who runs them

Industry 48 · Other 18

argenx (48) · Shanghai Zhongshan Hospital (2) · Stanford University (1) · Beijing Tiantan Hospital (1) · M. Peter Marinkovich (1) · University of South Florida (1) · Zhongming Qiu (1) · First Affiliated Hospital of Wenzhou Medical University (1)

Often tested with

Tested in the same studies.

Hyaluronidase (human recombinant) (22) · Thymectomy (1) · Telitacicept (1) · Methylprednisolone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Efgartigimod alfa is the comparator. A study of two new drugs counts under both.

  • 1Nipocalimab · Janssen Research & Development, LLC · next primary completion Sep 2027
Reaching primary completion within a year · 14, 6 in phase 3

Studies that test efgartigimod alfa, phase 3 first.

Studies

Open first, then newest update. How each study uses efgartigimod alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 66

See all 66 studies that test efgartigimod alfa →

As the comparator · 1 — what is tested is compared with efgartigimod alfa

Codes

What other systems call efgartigimod alfa · ClinicalTrials.gg INT001674

  • MeSH (NLM) C000718373efgartigimod alfaConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 961YV2O515EFGARTIGIMOD ALFAConfirmed FDA, NLM, Wikidata
  • RxNorm 2587717One source FDA
  • Wikidata Q110271677efgartigimod alfaConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C171817Efgartigimod AlfaOne source FDA
  • DrugBank DB15270One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.